erenumab
Selected indexed studies
- Erenumab. (, 2006) [PMID:30000991]
- Erenumab for episodic migraine. (Pain Manag, 2022) [PMID:35313740]
- A Controlled Trial of Erenumab for Episodic Migraine. (N Engl J Med, 2017) [PMID:29171821]
_Worker-drafted node — pending editorial review._
Connections
erenumab is a side effect of
Sources
- Erenumab. (2006) pubmed
- Erenumab for episodic migraine. (2022) pubmed
- A Controlled Trial of Erenumab for Episodic Migraine. (2017) pubmed
- Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. (2022) pubmed
- Erenumab. (2012) pubmed
- Erenumab: First Global Approval. (2018) pubmed
- Erenumab efficacy in migraine headache prophylaxis: A systematic review. (2023) pubmed
- Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention. (2019) pubmed
- Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial. (2024) pubmed
- Erenumab dosage for migraine prevention: An evidence-based narrative review with recommendations. (2022) pubmed